Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
Open Access
- 1 January 2021
- journal article
- review article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (5) , 1318-1333
Abstract
Aim: To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI) two-drug combination therapy in patients with advanced malignancy.Keywords
This publication has 37 references indexed in Scilit:
- Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface–Associated CalreticulinCancer Research, 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Primer on tumor immunology and cancer immunotherapyJournal for ImmunoTherapy of Cancer, 2013
- Structure and Interactions of the Human Programmed Cell Death 1 ReceptorJournal of Biological Chemistry, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell toleranceBlood, 2010
- Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort studyAnnals of Oncology, 2009
- B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturationProceedings of the National Academy of Sciences, 2009
- The Protective Role of Melanin Against UV Damage in Human Skin†Photochemistry and Photobiology, 2007